News

ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients

Peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) published in the New England Journal of Medicine showed that baricitinib in combination with remdesivir reduces recovery time, improves clinical status and demonstrates a trend towards a decrease in mortality  in hospitalised COVID-19 patients with pneumonia.

Those who took both drugs had a median time to recovery of seven days, compared with eight days for those who took only remdesivir. But for people who were on the edge of requiring invasive ventilation, median recovery time fell from 18 days on remdesivir alone to 10 days on both drugs.

This publication follows November’s announcement that baricitinib, first identified as a potential treatment by the BenevolentAI team in February, was granted Emergency Use Authorisation (EUA) by the U.S. Food and Drug Administration (FDA) for use in hospitalised COVID-19 patients who require supplemental oxygen or invasive mechanical ventilation. This latest data further supports the FDA’s decision to issue a EUA, again validating our AI-derived hypothesis for baricitinib as a COVID-19 treatment option. 

The urgency of the pandemic heightened the need to identify therapeutic options for patients suffering from severe symptoms of COVID-19. In the last week of January, our CEO, Joanna Shields, asked our team how we could best leverage our technology to combat this public health emergency. Our scientists were a step ahead and were already using the Benevolent Platform® to investigate options.

Following our discovery and scientific collaboration with Eli Lilly, baricitinib was dosed in patients in an unprecedented time frame. While vaccines and mass immunisations will be key to curbing the spread of COVID-19, therapeutic options for infected patients will continue to be crucial in reducing morbidity and mortality from this deadly virus. 

Baricitinib is a rheumatoid arthritis drug, owned and marketed by Eli Lilly under the brand name Olumiant™ and is now available as a treatment for hospitalised COVID-19 patients under EUA.


More Posts

You Might Also Like

News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
Video
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022
News
BenevolentAI joins the World Economic Forum’s Global Innovators Community
BenevolentAI joins the World Economic Forum’s Global Innovators Community to help ethically deploy AI to create a more sustainable, inclusive and resilient world.
Apr 21, 2022